Endometrial Serous AdenocarcinomaNCT02315469
Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery
An observational study of Endometrial Serous Adenocarcinoma and Fallopian Tube Carcinoma, run by NRG Oncology at 393 sites in 2 countries.
Trial summary
This research trial studies comprehensive patient questionnaires in predicting complications in older patients with gynecologic cancer undergoing surgery. Comprehensive patient questionnaires completed before surgery may help identify complications, such as the need for assistance in taking medications, decreased… Read more about this study
- Who is it for?
- Ages 70 years and older, women only
- Conditions the study is for
- Endometrial Serous Adenocarcinoma, Fallopian Tube Carcinoma, Malignant Female Reproductive System Neoplasm
- What is being tested?
- Comprehensive Geriatric Assessment and Questionnaire Administration
- How many people
- 190 participants
- Where
- 393 sitesin 2 countries
- Study dates
- 10 Feb 2015to 9 Feb 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 70 years and older
- Women only
- No healthy volunteers
- Older adult
Study population: Elderly women with suspected ovarian, fallopian tube, primary peritoneal or advanced stage papillary serous uterine carcinoma undergoing open cytoreductive surgery
Who may be able to join
- Patients with suspected ovarian, fallopian tube, primary peritoneal carcinomas or advanced stage papillary serous uterine carcinoma irrespective of performance status; this clinical determination is made by the treating physician
- Patients must have signed an approved informed consent and authorization permitting release of personal health information
- Patients who can understand sufficiently to be able to respond to questions posed by the study instruments
- Patients and/or caregiver (durable power of attorney) can give consent and caregiver can assist with the responses to questionnaire
- NOTE: it is the intent of this trial that all patients 70 years or older presenting to the participating physician/center be offered enrollment onto this study; eligible patients may enroll and subsequently receive neoadjuvant chemotherapy followed by interval surgery, primary cytoreductive surgery or no surgery at all
- Post-operative pathology will not exclude patients from this study
Who cannot join
- Patients whose circumstances at the time of study entry do not permit completion of the study or required follow-up
- Patients who would have planned surgery performed by the minimally invasive technique; institutions which perform cytoreductive surgery via the minimally invasive technique should not participate in this study; the minimally invasive surgery (MIS) technique is also not considered standard technique for primary cytoreductive surgery for advanced stage ovarian, fallopian tube or peritoneal cancers
- Patients who receive chemotherapy treatment (for a gynecologic malignancy) prior to consideration of enrollment into this trial and taking the geriatric assessment will be excluded
- Patients who have a known pre-operative primary uterine cancer, confirmed by endometrial biopsy
Trial locations and contacts
393 sites in 2 countries.
301 sites in 2 countries
United States300 sites
Jefferson Abington Hospital
Abington, Pennsylvania, 19001
Cleveland Clinic Akron General
Akron, Ohio, 44307
Women's Cancer Care Associates LLC
Albany, New York, 12208
University of New Mexico Cancer Center
Albuquerque, New Mexico, 87102
Southwest Gynecologic Oncology Associates Inc
Albuquerque, New Mexico, 87106
American Fork Hospital / Huntsman Intermountain Cancer Center
American Fork, Utah, 84003
AnMed Health Cancer Center
Anderson, South Carolina, 29621
Kaiser Permanente-Deer Valley Medical Center
Antioch, California, 94531
Northside Hospital
Atlanta, Georgia, 30342
MultiCare Auburn Medical Center
Auburn, Washington, 98001
Rocky Mountain Cancer Centers-Aurora
Aurora, Colorado, 80012
The Medical Center of Aurora
Aurora, Colorado, 80012
University of Colorado Hospital
Aurora, Colorado, 80045
Dell Seton Medical Center at The University of Texas
Austin, Texas, 78701
Virginia Mason Bainbridge Island Medical Center
Bainbridge Island, Washington, 98110
University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland, 21201
Sinai Hospital of Baltimore
Baltimore, Maryland, 21215
Flaget Memorial Hospital
Bardstown, Kentucky, 40004
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, 07920
Bronson Battle Creek
Battle Creek, Michigan, 49017
UHHS-Chagrin Highlands Medical Center
Beachwood, Ohio, 44122
Overlake Medical Center
Bellevue, Washington, 98004
Strecker Cancer Center-Belpre
Belpre, Ohio, 45714
Billings Clinic Cancer Center
Billings, Montana, 59101
Saint Vincent Healthcare
Billings, Montana, 59101
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233
Saint Joseph Medical Center
Bloomington, Illinois, 61701
Illinois CancerCare-Bloomington
Bloomington, Illinois, 61704
Prisma Health Cancer Institute - Spartanburg
Boiling Springs, South Carolina, 29316
Saint Luke's Cancer Institute - Boise
Boise, Idaho, 83712
Parkland Health Center-Bonne Terre
Bonne Terre, Missouri, 63628
Boulder Community Hospital
Boulder, Colorado, 80301
Rocky Mountain Cancer Centers-Boulder
Boulder, Colorado, 80304
Bozeman Deaconess Hospital
Bozeman, Montana, 59715
Harrison HealthPartners Hematology and Oncology-Bremerton
Bremerton, Washington, 98310
Harrison Medical Center
Bremerton, Washington, 98310
Highline Medical Center-Main Campus
Burien, Washington, 98166
University of Vermont Medical Center
Burlington, Vermont, 05401
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
Saint James Community Hospital and Cancer Treatment Center
Butte, Montana, 59701
Cooper Hospital University Medical Center
Camden, New Jersey, 08103
Illinois CancerCare-Canton
Canton, Illinois, 61520
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Southeast Cancer Center
Cape Girardeau, Missouri, 63703
Memorial Hospital of Carbondale
Carbondale, Illinois, 62902
Illinois CancerCare-Carthage
Carthage, Illinois, 62321
Sandra L Maxwell Cancer Center
Cedar City, Utah, 84720
Centralia Oncology Clinic
Centralia, Illinois, 62801
Cancer Center of Kansas - Chanute
Chanute, Kansas, 66720
Medical University of South Carolina
Charleston, South Carolina, 29425
Novant Health Presbyterian Medical Center
Charlotte, North Carolina, 28204
University of Virginia Cancer Center
Charlottesville, Virginia, 22908
Memorial Hospital
Chattanooga, Tennessee, 37404
Cheyenne Regional Medical Center-West
Cheyenne, Wyoming, 82001
Northwestern University
Chicago, Illinois, 60611
Rush University Medical Center
Chicago, Illinois, 60612
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637
Adena Regional Medical Center
Chillicothe, Ohio, 45601
Oncology Hematology Care Inc-Eden Park
Cincinnati, Ohio, 45202
Good Samaritan Hospital - Cincinnati
Cincinnati, Ohio, 45220
Bethesda North Hospital
Cincinnati, Ohio, 45242
TriHealth Cancer Institute-Westside
Cincinnati, Ohio, 45247
TriHealth Cancer Institute-Anderson
Cincinnati, Ohio, 45255
Case Western Reserve University
Cleveland, Ohio, 44106
Medical Oncology and Hematology Associates-West Des Moines
Clive, Iowa, 50325
Mercy Cancer Center-West Lakes
Clive, Iowa, 50325
Big Horn Basin Cancer Center
Cody, Wyoming, 82414
Billings Clinic-Cody
Cody, Wyoming, 82414
Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho, 83814
Penrose-Saint Francis Healthcare
Colorado Springs, Colorado, 80907
Rocky Mountain Cancer Centers-Penrose
Colorado Springs, Colorado, 80907
Columbus Oncology and Hematology Associates Inc
Columbus, Ohio, 43214
Riverside Methodist Hospital
Columbus, Ohio, 43214
Grant Medical Center
Columbus, Ohio, 43215
The Mark H Zangmeister Center
Columbus, Ohio, 43219
Mount Carmel Health Center West
Columbus, Ohio, 43222
Doctors Hospital
Columbus, Ohio, 43228
Memorial Sloan Kettering Commack
Commack, New York, 11725
John Muir Medical Center-Concord Campus
Concord, California, 94520
Mercy Hospital
Coon Rapids, Minnesota, 55433
Baptist Health Corbin
Corbin, Kentucky, 40701
Commonwealth Cancer Center-Corbin
Corbin, Kentucky, 40701
Alegent Health Mercy Hospital
Council Bluffs, Iowa, 51503
Michiana Hematology Oncology PC-Crown Point
Crown Point, Indiana, 46307
Parkland Memorial Hospital
Dallas, Texas, 75235
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, 75390
Geisinger Medical Center
Danville, Pennsylvania, 17822
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois, 62526
Decatur Memorial Hospital
Decatur, Illinois, 62526
Delaware Health Center-Grady Cancer Center
Delaware, Ohio, 43015
Delaware Radiation Oncology
Delaware, Ohio, 43015
Grady Memorial Hospital
Delaware, Ohio, 43015
Porter Adventist Hospital
Denver, Colorado, 80210
Colorado Blood Cancer Institute
Denver, Colorado, 80218
Presbyterian - Saint Lukes Medical Center - Health One
Denver, Colorado, 80218
Rocky Mountain Cancer Centers-Midtown
Denver, Colorado, 80218
SCL Health Saint Joseph Hospital
Denver, Colorado, 80218
Rocky Mountain Cancer Centers-Rose
Denver, Colorado, 80220
Rose Medical Center
Denver, Colorado, 80220
Western States Cancer Research NCORP
Denver, Colorado, 80222
Medical Oncology and Hematology Associates-Laurel
Des Moines, Iowa, 50314
Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, 48201
Henry Ford Hospital
Detroit, Michigan, 48202
Cancer Center of Kansas - Dodge City
Dodge City, Kansas, 67801
Wentworth-Douglass Hospital
Dover, New Hampshire, 03820
Mercy Medical Center
Durango, Colorado, 81301
Southwest Oncology PC
Durango, Colorado, 81301
Duke University Medical Center
Durham, North Carolina, 27710
Prisma Health Cancer Institute - Easley
Easley, South Carolina, 29640
Marshfield Clinic Cancer Center at Sacred Heart
Eau Claire, Wisconsin, 54701
Saint Elizabeth Medical Center South
Edgewood, Kentucky, 41017
Fairview Southdale Hospital
Edina, Minnesota, 55435
Crossroads Cancer Center
Effingham, Illinois, 62401
Cancer Center of Kansas - El Dorado
El Dorado, Kansas, 67042
Baptist Health Hardin
Elizabethtown, Kentucky, 42701
Michiana Hematology Oncology PC-Elkhart
Elkhart, Indiana, 46514
Mountain Blue Cancer Care Center - Swedish
Englewood, Colorado, 80113
Swedish Medical Center
Englewood, Colorado, 80113
Saint Elizabeth Hospital
Enumclaw, Washington, 98022
Illinois CancerCare-Eureka
Eureka, Illinois, 61530
Fairbanks Memorial Hospital
Fairbanks, Alaska, 99701
Weisberg Cancer Treatment Center
Farmington Hills, Michigan, 48334
Virginia Mason Federal Way Medical Center
Federal Way, Washington, 98002
Saint Francis Hospital
Federal Way, Washington, 98003
Cancer Center of Kansas - Fort Scott
Fort Scott, Kansas, 66701
Radiation Oncology Associates PC
Fort Wayne, Indiana, 46804
Parkview Hospital Randallia
Fort Wayne, Indiana, 46805
Kaiser Permanente-Fremont
Fremont, California, 94538
Kaiser Permanente-Fresno
Fresno, California, 93720
Unity Hospital
Fridley, Minnesota, 55432
Saint Luke's Cancer Institute - Fruitland
Fruitland, Idaho, 83619
University of Florida Health Science Center - Gainesville
Gainesville, Florida, 32610
Illinois CancerCare-Galesburg
Galesburg, Illinois, 61401
Western Illinois Cancer Treatment Center
Galesburg, Illinois, 61401
Tacoma/Valley Radiation Oncology Centers-Gig Harbor
Gig Harbor, Washington, 98332
MultiCare Gig Harbor Medical Park
Gig Harbor, Washington, 98335
Mountain Blue Cancer Care Center
Golden, Colorado, 80401
CHI Health Saint Francis
Grand Island, Nebraska, 68803
Mercy Health Saint Mary's
Grand Rapids, Michigan, 49503
Spectrum Health at Butterworth Campus
Grand Rapids, Michigan, 49503
Benefis Healthcare- Sletten Cancer Institute
Great Falls, Montana, 59405
North Colorado Medical Center
Greeley, Colorado, 80631
Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin, 54301
Greenville Health System Cancer Institute-Andrews
Greenville, South Carolina, 29601
Prisma Health Cancer Institute - Butternut
Greenville, South Carolina, 29605
Prisma Health Cancer Institute - Faris
Greenville, South Carolina, 29605
Prisma Health Greenville Memorial Hospital
Greenville, South Carolina, 29605
Prisma Health Cancer Institute - Eastside
Greenville, South Carolina, 29615
Rocky Mountain Cancer Centers-Greenwood Village
Greenwood Village, Colorado, 80111
Prisma Health Cancer Institute - Greer
Greer, South Carolina, 29650
Memorial Sloan Kettering Westchester
Harrison, New York, 10604
Hartford Hospital
Hartford, Connecticut, 06102
Geisinger Medical Center-Cancer Center Hazleton
Hazleton, Pennsylvania, 18201
Saint Peter's Community Hospital
Helena, Montana, 59601
Pulmonary Medicine Center of Chattanooga-Hixson
Hixson, Tennessee, 37343
Kaiser Permanente Moanalua Medical Center
Honolulu, Hawaii, 96819
Hutchinson Area Health Care
Hutchinson, Minnesota, 55350
Cancer Center of Kansas-Independence
Independence, Kansas, 67301
Indiana University/Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202
Sidney and Lois Eskenazi Hospital
Indianapolis, Indiana, 46202
University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, 52242
Kaiser Permanente-Irvine
Irvine, California, 92618
Saint Dominic-Jackson Memorial Hospital
Jackson, Mississippi, 39216
Capital Region Southwest Campus
Jefferson City, Missouri, 65109
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
West Michigan Cancer Center
Kalamazoo, Michigan, 49007
Borgess Medical Center
Kalamazoo, Michigan, 49048
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Heartland Hematology and Oncology
Kearney, Nebraska, 68845
CHI Health Good Samaritan
Kearney, Nebraska, 68847
Northwest Cancer Clinic
Kennewick, Washington, 99336
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois, 61443
Cancer Center of Kansas-Kingman
Kingman, Kansas, 67068
Gundersen Lutheran Medical Center
La Crosse, Wisconsin, 54601
UC San Diego Moores Cancer Center
La Jolla, California, 92093
Lakeland Regional Health Hollis Cancer Center
Lakeland, Florida, 33805
Rocky Mountain Cancer Centers-Lakewood
Lakewood, Colorado, 80228
Saint Anthony Hospital
Lakewood, Colorado, 80228
Saint Clare Hospital
Lakewood, Washington, 98499
Fairfield Medical Center
Lancaster, Ohio, 43130
Women's Cancer Center of Nevada
Las Vegas, Nevada, 89169
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, 03756
Geisinger Medical Oncology-Lewisburg
Lewisburg, Pennsylvania, 17837
Baptist Health Lexington
Lexington, Kentucky, 40503
Saint Joseph Radiation Oncology Resource Center
Lexington, Kentucky, 40504
Saint Joseph Hospital East
Lexington, Kentucky, 40509
Cancer Center of Kansas-Liberal
Liberal, Kansas, 67905
Saint Elizabeth Regional Medical Center
Lincoln, Nebraska, 68510
Rocky Mountain Cancer Centers-Littleton
Littleton, Colorado, 80120
Littleton Adventist Hospital
Littleton, Colorado, 80122
Logan Regional Hospital
Logan, Utah, 84321
Loma Linda University Medical Center
Loma Linda, California, 92354
Rocky Mountain Cancer Centers-Sky Ridge
Lone Tree, Colorado, 80124
Sky Ridge Medical Center
Lone Tree, Colorado, 80124
Longmont United Hospital
Longmont, Colorado, 80501
Rocky Mountain Cancer Centers-Longmont
Longmont, Colorado, 80501
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, 90027
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095
Jewish Hospital
Louisville, Kentucky, 40202
Saints Mary and Elizabeth Hospital
Louisville, Kentucky, 40215
Jewish Hospital Medical Center Northeast
Louisville, Kentucky, 40245
McKee Medical Center
Loveland, Colorado, 80539
Virginia Mason Lynnwood Medical Center
Lynnwood, Washington, 98036
Illinois CancerCare-Macomb
Macomb, Illinois, 61455
Baptist Health Madisonville/Merle Mahr Cancer Center
Madisonville, Kentucky, 42431
Minnesota Oncology Hematology PA-Maplewood
Maplewood, Minnesota, 55109
Saint John's Hospital - Healtheast
Maplewood, Minnesota, 55109
Marietta Memorial Hospital
Marietta, Ohio, 45750
OhioHealth Marion General Hospital
Marion, Ohio, 43302
Marshfield Medical Center-Marshfield
Marshfield, Wisconsin, 54449
UH Seidman Cancer Center at Landerbrook Health Center
Mayfield Heights, Ohio, 44124
Loyola University Medical Center
Maywood, Illinois, 60153
UH Seidman Cancer Center at Lake Health Mentor Campus
Mentor, Ohio, 44060
Saint Luke's Cancer Institute - Meridian
Meridian, Idaho, 83642
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center
Minneapolis, Minnesota, 55415
Health Partners Inc
Minneapolis, Minnesota, 55454
Marshfield Clinic-Minocqua Center
Minocqua, Wisconsin, 54548
Michiana Hematology Oncology PC-Mishawaka
Mishawaka, Indiana, 46545
Saint Patrick Hospital - Community Hospital
Missoula, Montana, 59802
Community Medical Hospital
Missoula, Montana, 59804
Kaiser Permanente-Modesto
Modesto, California, 95356
Monongalia Hospital
Morgantown, West Virginia, 26505
Morristown Medical Center
Morristown, New Jersey, 07960
Knox Community Hospital
Mount Vernon, Ohio, 43050
ProHealth D N Greenwald Center
Mukwonago, Wisconsin, 53149
Intermountain Medical Center
Murray, Utah, 84107
Mercy Health Mercy Campus
Muskegon, Michigan, 49444
Saint Luke's Cancer Institute - Nampa
Nampa, Idaho, 83686
The Hospital of Central Connecticut
New Britain, Connecticut, 06050
UC Comprehensive Cancer Center at Silver Cross
New Lenox, Illinois, 60451
Cancer Center of Western Wisconsin
New Richmond, Wisconsin, 54017
New Ulm Medical Center
New Ulm, Minnesota, 56073
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
Licking Memorial Hospital
Newark, Ohio, 43055
Newark Radiation Oncology
Newark, Ohio, 43055
Cancer Center of Kansas - Newton
Newton, Kansas, 67114
Lakeland Hospital Niles
Niles, Michigan, 49120
Cancer Care Center of O'Fallon
O'Fallon, Illinois, 62269
Kaiser Permanente-Oakland
Oakland, California, 94611
ProHealth Oconomowoc Memorial Hospital
Oconomowoc, Wisconsin, 53066
McKay-Dee Hospital Center
Ogden, Utah, 84403
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
Nebraska Methodist Hospital
Omaha, Nebraska, 68114
Alegent Health Immanuel Medical Center
Omaha, Nebraska, 68122
Hematology and Oncology Consultants PC
Omaha, Nebraska, 68122
Alegent Health Bergan Mercy Medical Center
Omaha, Nebraska, 68124
Alegent Health Lakeside Hospital
Omaha, Nebraska, 68130
Creighton University Medical Center
Omaha, Nebraska, 68131
University of Nebraska Medical Center
Omaha, Nebraska, 68198
Memorial GYN Plus
Ooltewah, Tennessee, 37363
Orlando Health Cancer Institute
Orlando, Florida, 32806
Illinois CancerCare-Ottawa Clinic
Ottawa, Illinois, 61350
Radiation Oncology of Northern Illinois
Ottawa, Illinois, 61350
Baptist Health Paducah
Paducah, Kentucky, 42003
Paoli Memorial Hospital
Paoli, Pennsylvania, 19301
Midlands Community Hospital
Papillion, Nebraska, 68046
Advocate Lutheran General Hospital
Park Ridge, Illinois, 60068
Parker Adventist Hospital
Parker, Colorado, 80138
Rocky Mountain Cancer Centers-Parker
Parker, Colorado, 80138
Cancer Center of Kansas - Parsons
Parsons, Kansas, 67357
Illinois CancerCare-Pekin
Pekin, Illinois, 61554
OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center
Pekin, Illinois, 61554
Sacred Heart Hospital
Pensacola, Florida, 32504
Illinois CancerCare-Peoria
Peoria, Illinois, 61615
OSF Saint Francis Radiation Oncology at Peoria Cancer Center
Peoria, Illinois, 61615
Methodist Medical Center of Illinois
Peoria, Illinois, 61636
OSF Saint Francis Medical Center
Peoria, Illinois, 61637
Illinois CancerCare-Peru
Peru, Illinois, 61354
Valley Radiation Oncology
Peru, Illinois, 61354
University of Pennsylvania/Abramson Cancer Center
Philadelphia, Pennsylvania, 19104
Saint Joseph's Hospital and Medical Center
Phoenix, Arizona, 85013
Michiana Hematology Oncology PC-Plymouth
Plymouth, Indiana, 46563
Southern Ohio Medical Center
Portsmouth, Ohio, 45662
Kootenai Clinic Cancer Services - Post Falls
Post Falls, Idaho, 83854
Geisinger Cancer Services-Pottsville
Pottsville, Pennsylvania, 17901
Harrison HealthPartners Hematology and Oncology-Poulsbo
Poulsbo, Washington, 98370
Peninsula Cancer Center
Poulsbo, Washington, 98370
Cancer Center of Kansas - Pratt
Pratt, Kansas, 67124
Illinois CancerCare-Princeton
Princeton, Illinois, 61356
Women and Infants Hospital
Providence, Rhode Island, 02905
Utah Valley Regional Medical Center
Provo, Utah, 84604
Saint Mary Corwin Medical Center
Pueblo, Colorado, 81004
Rocky Mountain Cancer Centers - Pueblo
Pueblo, Colorado, 81008
MultiCare Good Samaritan Hospital
Puyallup, Washington, 98372
Tacoma/Valley Radiation Oncology Centers-Puyallup
Puyallup, Washington, 98372
Kaiser Permanente-Redwood City
Redwood City, California, 94063
Spectrum Health Reed City Hospital
Reed City, Michigan, 49677
Marshfield Medical Center-Rice Lake
Rice Lake, Wisconsin, 54868
Kaiser Permanente-Richmond
Richmond, California, 94801
North Memorial Medical Health Center
Robbinsdale, Minnesota, 55422
Mayo Clinic in Rochester
Rochester, Minnesota, 55905
Kaiser Permanente-Roseville
Roseville, California, 95661
Kaiser Permanente-South Sacramento
Sacramento, California, 95823
Kaiser Permanente - Sacramento
Sacramento, California, 95825
Coborn Cancer Center at Saint Cloud Hospital
Saint Cloud, Minnesota, 56303
Saint Cloud Hospital
Saint Cloud, Minnesota, 56303
Canada1 site
McGill University Department of Oncology
Montreal, Quebec, H2W 1S6
About this study
Official title: Pre-operative Assessment and Post-Operative Outcomes of Elderly Women With Gynecologic Cancers
This research trial studies comprehensive patient questionnaires in predicting complications in older patients with gynecologic cancer undergoing surgery. Comprehensive patient questionnaires completed before surgery may help identify complications, such as the need for assistance in taking medications, decreased mobility, decreased social activity, and falls, and may improve outcomes for older patients with gynecologic cancer.
Read the detailed description
PRIMARY OBJECTIVES:
- To determine whether the preoperative geriatric assessment (GA)-gynecology (GYN) score will be associated with major post-operative complications in elderly patients undergoing open primary cytoreduction surgery.
SECONDARY OBJECTIVES:
- To explore associations between individual variables of the preoperative geriatric assessment and major post-operative complications in patients undergoing open primary cytoreduction surgery.
II. To assess the association between the preoperative GA-GYN score and cytoreducibility defined by extent of residual disease in patients undergoing open primary cytoreduction surgery.
TERTIARY OBJECTIVES :
- To evaluate whether the preoperative GA-GYN scores obtained before and after neoadjuvant chemotherapy will be associated with major postoperative complications in elderly patients undergoing open interval cytoreduction surgery.
II. To describe reasons why surgeons at centers where open cytoreduction surgery is the standard of care choose to perform interval surgery vs primary surgery, and to explore the association of the preoperative GA-GYN score with the decision to perform primary surgery or interval surgery or no surgery.
III. To collect the following specific information on how elderly women with suspected ovarian, fallopian tube, primary peritoneal carcinomas or advanced stage papillary serous uterine carcinoma are treated at centers that consider open cytoreduction surgery the standard of care: (1) the percentage of patients treated with primary open cytoreduction vs. interval open cytoreduction vs. no surgery and (2) to ascertain the extent of cytoreduction.
IV. To determine whether neoadjuvant chemotherapy will be associated with changes in the GA-GYN score to change by comparing the GA-GYN scores obtained before and after neoadjuvant chemotherapy.
- To determine whether 30-day readmission rates after cytoreductive surgery correlate with the GA-GYN score.
OUTLINE:
At time of consent and within 14 days of surgery, patients complete a pre-operative geriatric assessment that evaluates functional status, comorbid medical conditions, psychological state, social support, and nutritional status. Post-operative complications are also collected for 6 weeks after surgery or until the date patients initiate or restart chemotherapy whichever is first.
- Conditions
- Endometrial Serous Adenocarcinoma, Fallopian Tube Carcinoma, Malignant Female Reproductive System Neoplasm, Ovarian Carcinoma, Primary Peritoneal Carcinoma, Stage IIIA Uterine Corpus Cancer AJCC v7
- Being tested
- Comprehensive Geriatric Assessment, Questionnaire Administration
- Medical subject headings
- Fallopian Tube Neoplasms, Ovarian Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Comprehensive Geriatric AssessmentOther
Complete pre-operative geriatric assessment
Questionnaire AdministrationOther
Ancillary studies
| Study group | Role | What they receive |
|---|---|---|
| Observational (geriatric assessment) | At time of consent and within 14 days of surgery, patients complete a pre-operative geriatric assessment that evaluates functional status, comorbid medical conditions, psychological state, social support, and nutritional status. Post-operative complications are also collected for 6 weeks after surgery or until the date patients initiate or restart chemotherapy whichever is first. Receives: Other: Comprehensive Geriatric Assessment; Other: Questionnaire Administration |
What is being measured
The primary outcome is the main question the study is designed to answer.
Occurrence of major post-operative complications outlined in The American College of Surgeons' National Surgical Quality Improvement Program
Measured: Up to 6 weeks after surgery
GA-GYN score, defined as the summation of the risk score for each risk factor derived from the predictive model including 5 risk factors from the GA and 3 other risk factors
Geriatric assessment variables are used in the predictive model; the risk factors will be used to derive the total score.
Measured: Up to 14 days before surgery
Secondary outcomes (12)
Extent of residual disease in patients undergoing open primary cytoreduction surgery
The association between the preoperative GA-GYN score and cytoreducibility defined by extent of residual disease in patients undergoing open primary cytoreduction surgery will be assessed. Cytoreducibility is defined as complete cytoreduction (maximum dimension of residual disease =< 0.1 cm), optimal cytoreduction (maximum dimension of residual disease greater than 0.1 cm but less than or equal to 1.0 cm), or suboptimal cytoreduction (maximum dimension of residual disease greater than 1.0 cm) according to extent of residual disease.
Measured: 6 weeks after surgery
Functional status, as measured by Instrumental Activities of Daily Living (IADL)
The IADL subscale consists of 7 questions rated on a 3-point Likert scale measuring the degree to which an activity can be performed independently.
Measured: Up to 14 days before surgery
Functional status, as measured by Activities of Daily Living (ADL)
The ALD uses a subscale of the Medical Outcomes Study physical health with 10 questions rated on a 3-point scale.
Measured: Up to 14 days before surgery
Patient's overall functioning, as measured by the physician rated performance rating scale
Measured: Up to 14 days before surgery
Patient's overall functioning, as measured by the self-reported performance rating scale
Measured: Up to 14 days before surgery
Number of falls in last 6 months
Measured: Up to 14 days before surgery
Comorbidity, as measured by the Older American Resources and Services (OARS) Physical Health section
The OARS Physical Health Section is a comorbidity scale that contains a list of current illnesses and conditions an individual might have, and the degree to which they impair daily activities, rated on a 3-point scale of " not at all" to " a great deal."
Measured: Up to 14 days before surgery
Psychological status, as measured by the Mental Health Inventory (MHI) that is based upon the General Well-Being Scale
The full length MHI consists of 38 items grouped into the following five subscales and three global scores: anxiety, depression, general positive affect, emotional ties, and loss of behavioral emotional control, Psychological Distress (negative affect), Psychological Well-Being (positive affect), and the MHI total score a 17 item version of the MHI will be used, which will yield three global scores of Psychological Distress, Psychological Well-Being and MHI total score, as in the original 38 item MHI.
Measured: Up to 14 days before surgery
Social functioning, as measured by the Medical Outcomes Study (MOS) Social Activity Limitations Measure
The four-item subscale identifies the extent to which physical or emotional problems interfere with an individual's social activities. All items are rated on a 5-point Likert scale, with response categories varying in each item. The mean of the total score is transformed to a scale of 0-100, with a higher number indicating greater support.
Measured: Up to 14 days before surgery
Social support, as measured by the MOS Social Support Survey
Measured: Up to 14 days before surgery
Nutritional status, as measured by BMI
Measured: Up to 14 days before surgery
Nutritional status, as measured by percentage unintentional weight loss in last 6 months
Measured: Up to 14 days before surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Dec 2014 (estimated)
- Study start10 Feb 2015
- Primary completion15 Mar 2016
- Study completion9 Feb 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Endometrial Serous AdenocarcinomaStudies of the same condition, open and under way.
- More trials run by NRG OncologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 190 participants (actual)
Sponsor and investigators
- Lead sponsor
- NRG Oncology
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Amina Ahmed, Principal investigator, NRG Oncology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02315469
- Sponsor's protocol ID
- NRG-CC002
- Other IDs
- NCI-2014-01376, GOG-ELD1301, NRG-CC002, NRG-CC002, NRG-CC002, U10CA101165, UG1CA189867
- Status last verified
- Nov 2021
- First submitted
- 9 Dec 2014
- Last updated
- 24 Nov 2021
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 24 Nov 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pre-operative Assessment and Post-Operative Outcomes of Elderly Women With Gynecologic Cancers
- ClinicalTrials.gov ID
- NCT02315469
- Acronym / sponsor ID
- NRG-CC002
- Conditions
- Endometrial Serous Adenocarcinoma, Fallopian Tube Carcinoma, Malignant Female Reproductive System Neoplasm, Ovarian Carcinoma, Primary Peritoneal Carcinoma, Stage IIIA Uterine Corpus Cancer AJCC v7
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 190 participants (actual)
- Lead sponsor
- NRG OncologyUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 10 Feb 2015 (actual)
- Primary completion
- 15 Mar 2016 (actual)
- Study completion
- 9 Feb 2019 (actual)
- First posted
- 11 Dec 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This research trial studies comprehensive patient questionnaires in predicting complications in older patients with gynecologic cancer undergoing surgery. Comprehensive patient questionnaires completed before surgery may help identify complications, such as the need for assistance in taking medications, decreased mobility, decreased social activity, and falls, and may improve outcomes for older patients with gynecologic cancer.
Detailed description
PRIMARY OBJECTIVES:
- To determine whether the preoperative geriatric assessment (GA)-gynecology (GYN) score will be associated with major post-operative complications in elderly patients undergoing open primary cytoreduction surgery.
SECONDARY OBJECTIVES:
- To explore associations between individual variables of the preoperative geriatric assessment and major post-operative complications in patients undergoing open primary cytoreduction surgery.
II. To assess the association between the preoperative GA-GYN score and cytoreducibility defined by extent of residual disease in patients undergoing open primary cytoreduction surgery.
TERTIARY OBJECTIVES :
- To evaluate whether the preoperative GA-GYN scores obtained before and after neoadjuvant chemotherapy will be associated with major postoperative complications in elderly patients undergoing open interval cytoreduction surgery.
II. To describe reasons why surgeons at centers where open cytoreduction surgery is the standard of care choose to perform interval surgery vs primary surgery, and to explore the association of the preoperative GA-GYN score with the decision to perform primary surgery or interval surgery or no surgery.
III. To collect the following specific information on how elderly women with suspected ovarian, fallopian tube, primary peritoneal carcinomas or advanced stage papillary serous uterine carcinoma are treated at centers that consider open cytoreduction surgery the standard of care: (1) the percentage of patients treated with primary open cytoreduction vs. interval open cytoreduction vs. no surgery and (2) to ascertain the extent of cytoreduction.
IV. To determine whether neoadjuvant chemotherapy will be associated with changes in the GA-GYN score to change by comparing the GA-GYN scores obtained before and after neoadjuvant chemotherapy.
- To determine whether 30-day readmission rates after cytoreductive surgery correlate with the GA-GYN score.
OUTLINE:
At time of consent and within 14 days of surgery, patients complete a pre-operative geriatric assessment that evaluates functional status, comorbid medical conditions, psychological state, social support, and nutritional status. Post-operative complications are also collected for 6 weeks after surgery or until the date patients initiate or restart chemotherapy whichever is first.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Observational (geriatric assessment) | – | Other: Comprehensive Geriatric Assessment, Other: Questionnaire AdministrationAt time of consent and within 14 days of surgery, patients complete a pre-operative geriatric assessment that evaluates functional status, comorbid medical conditions, psychological state, social support, and nutritional status. Post-operative complications are also collected for 6 weeks after surgery or until the date patients initiate or restart chemotherapy whichever is first. |
Who may qualify
- Ages
- 70 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- Elderly women with suspected ovarian, fallopian tube, primary peritoneal or advanced stage papillary serous uterine carcinoma undergoing open cytoreductive surgery
Key inclusion criteria (6 listed)
- Patients with suspected ovarian, fallopian tube, primary peritoneal carcinomas or advanced stage papillary serous uterine carcinoma irrespective of performance status; this clinical determination is made by the treating physician
- Patients must have signed an approved informed consent and authorization permitting release of personal health information
- Patients who can understand sufficiently to be able to respond to questions posed by the study instruments
- Patients and/or caregiver (durable power of attorney) can give consent and caregiver can assist with the responses to questionnaire
- Post-operative pathology will not exclude patients from this study
Key exclusion criteria (4 listed)
- Patients whose circumstances at the time of study entry do not permit completion of the study or required follow-up
- Patients who would have planned surgery performed by the minimally invasive technique; institutions which perform cytoreductive surgery via the minimally invasive technique should not participate in this study; the minimally invasive surgery (MIS) technique is also not considered standard technique for primary cytoreductive surgery for advanced stage ovarian, fallopian tube or peritoneal cancers
- Patients who receive chemotherapy treatment (for a gynecologic malignancy) prior to consideration of enrollment into this trial and taking the geriatric assessment will be excluded
- Patients who have a known pre-operative primary uterine cancer, confirmed by endometrial biopsy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Comprehensive Geriatric AssessmentComplete pre-operative geriatric assessment | Other | Observational (geriatric assessment) |
| Questionnaire AdministrationAncillary studies | Other | Observational (geriatric assessment) |
Primary outcome
Occurrence of major post-operative complications outlined in The American College of Surgeons' National Surgical Quality Improvement Program
Time frame: Up to 6 weeks after surgery
GA-GYN score, defined as the summation of the risk score for each risk factor derived from the predictive model including 5 risk factors from the GA and 3 other risk factors
Time frame: Up to 14 days before surgery
Geriatric assessment variables are used in the predictive model; the risk factors will be used to derive the total score.
12 secondary outcomes
Extent of residual disease in patients undergoing open primary cytoreduction surgery
Time frame: 6 weeks after surgery
Functional status, as measured by Instrumental Activities of Daily Living (IADL)
Time frame: Up to 14 days before surgery
Functional status, as measured by Activities of Daily Living (ADL)
Time frame: Up to 14 days before surgery
Patient's overall functioning, as measured by the physician rated performance rating scale
Time frame: Up to 14 days before surgery
Patient's overall functioning, as measured by the self-reported performance rating scale
Time frame: Up to 14 days before surgery
Number of falls in last 6 months
Time frame: Up to 14 days before surgery
Comorbidity, as measured by the Older American Resources and Services (OARS) Physical Health section
Time frame: Up to 14 days before surgery
Psychological status, as measured by the Mental Health Inventory (MHI) that is based upon the General Well-Being Scale
Time frame: Up to 14 days before surgery
Social functioning, as measured by the Medical Outcomes Study (MOS) Social Activity Limitations Measure
Time frame: Up to 14 days before surgery
Social support, as measured by the MOS Social Support Survey
Time frame: Up to 14 days before surgery
Nutritional status, as measured by BMI
Time frame: Up to 14 days before surgery
Nutritional status, as measured by percentage unintentional weight loss in last 6 months
Time frame: Up to 14 days before surgery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Nov 2021.
Related trials for Endometrial Serous Adenocarcinoma
Active, not recruitingPhase 2
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma
Active, not recruitingPhase 3
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma
RecruitingPhase 1
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma
Recruiting
Safety, Efficacy and Quality of Life After Adjuvant Hypofractionated Radiotherapy for Endometrial Cancer
Endometrial Cancer, Endometrial Adenocarcinoma
Active, not recruiting
PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer
Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Amina Ahmed principal investigator
NRG Oncology
393 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Endometrial Serous Adenocarcinoma and Fallopian Tube Carcinoma, run by NRG Oncology at 393 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 393 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Occurrence of major post-operative complications outlined in The American College of Surgeons' National Surgical Quality Improvement Program (time frame: Up to 6 weeks after surgery). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Nov 2021.